174 related articles for article (PubMed ID: 16407713)
1. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders.
Chan DC; Barrett PH; Watts GF
Curr Opin Lipidol; 2006 Feb; 17(1):28-36. PubMed ID: 16407713
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
[TBL] [Abstract][Full Text] [Related]
3. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
Chan DC; Barrett PH; Watts GF
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
Chan DC; Barrett PH; Watts GF
Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
[TBL] [Abstract][Full Text] [Related]
5. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
Watts GF; Chan DC; Ooi EM; Nestel PJ; Beilin LJ; Barrett PH
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):877-82. PubMed ID: 16922825
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the investigation of lipoprotein metabolism using tracer methodology.
Chan DC; Watts GF
Clin Lab; 2006; 52(7-8):353-61. PubMed ID: 16955633
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
8. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
Vaziri ND
Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
[TBL] [Abstract][Full Text] [Related]
9. [Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms].
Zák A; Slabý A
Cas Lek Cesk; 2008; 147(9):459-70. PubMed ID: 18988488
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
Kwiterovich PO
Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
[TBL] [Abstract][Full Text] [Related]
14. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.
Chapman MJ; Orsoni A; Robillard P; Therond P; Giral P
J Clin Lipidol; 2018; 12(3):784-800.e4. PubMed ID: 29574070
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
Chan DC; Watts GF
Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
[TBL] [Abstract][Full Text] [Related]
16. Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.
Ying Q; Chan DC; Barrett PHR; Watts GF
Metabolism; 2021 Nov; 124():154887. PubMed ID: 34508741
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
Le Goff W; Guerin M; Chapman MJ
Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
[TBL] [Abstract][Full Text] [Related]
19. Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism.
Chan DC; Barrett PH; Watts GF
Curr Opin Lipidol; 2016 Dec; 27(6):550-556. PubMed ID: 27749370
[TBL] [Abstract][Full Text] [Related]
20. A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans.
Ouguerram K; Krempf M; Maugeais C; Maugère P; Darmaun D; Magot T
Metabolism; 2002 Jan; 51(1):5-11. PubMed ID: 11782865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
